BIOMAT Database Logo BIOMAT Database Logo

The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein. 2017

N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Biogen, Cambridge, MA, USA.

Essentials Recombinant factor VIII (rFVIII) Fc fusion protein has a 1.5-fold longer half-life than rFVIII. Five orthogonal methods were used to characterize the structure of rFVIIIFc compared to rFVIII. The C-terminal Fc fusion does not perturb the structure of FVIII in rFVIIIFc. The FVIII and Fc components of rFVIIIFc are flexibly tethered and functionally independent. Background Fusion of the human IgG1 Fc domain to the C-terminal C2 domain of B-domain-deleted (BDD) factor VIII (FVIII) results in the recombinant FVIII Fc (rFVIIIFc) fusion protein, which has a 1.5-fold longer half-life in humans. Objective To assess the structural properties of rFVIIIFc by comparing its constituent FVIII and Fc elements with their respective isolated components, and evaluating their structural independence within rFVIIIFc. Methods rFVIIIFc and its isolated FVIII and Fc components were compared by the use of hydrogen-deuterium exchange mass spectrometry (HDX-MS). The structure of rFVIIIFc was also evaluated by the use of X-ray crystallography, small-angle X-ray scattering (SAXS), and electron microscopy (EM). The degree of steric interference by the appended Fc domain was assessed by EM and surface plasmon resonance (SPR). Results HDX-MS analysis of rFVIIIFc revealed that fusion caused no structural perturbations in FVIII or Fc. The rFVIIIFc crystal structure showed that the FVIII component is indistinguishable from published BDD FVIII structures. The Fc domain was not observed, indicating high mobility. SAXS analysis was consistent with an ensemble of rigid-body models in which the Fc domain exists in a largely extended orientation relative to FVIII. Binding of Fab fragments of anti-C2 domain antibodies to BDD FVIII was visualized by EM, and the affinities of the corresponding intact antibodies for BDD FVIII and rFVIIIFc were comparable by SPR analysis. Conclusions The FVIII and Fc components of rFVIIIFc are structurally indistinguishable from their isolated constituents, and show a high degree of structural independence, consistent with the functional comparability of rFVIIIFc and unmodified FVIII.

UI MeSH Term Description Entries
D007141 Immunoglobulin Fc Fragments Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fc Fragment,Fc Fragments,Fc Immunoglobulin,Fc Immunoglobulins,Ig Fc Fragments,Immunoglobulin Fc Fragment,Immunoglobulins, Fc,Immunoglobulins, Fc Fragment,Fc Fragment Immunoglobulins,Fc Fragment, Immunoglobulin,Fc Fragments, Ig,Fc Fragments, Immunoglobulin,Fragment Immunoglobulins, Fc,Fragment, Fc,Fragments, Ig Fc,Immunoglobulin, Fc
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008854 Microscopy, Electron Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen. Electron Microscopy
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.
July 2015, Biologicals : journal of the International Association of Biological Standardization,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
July 2016, Thrombosis and haemostasis,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
January 2013, Journal of thrombosis and haemostasis : JTH,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
January 2015, Clinical pharmacology in drug development,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.
November 2018, Blood advances,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation.
January 2024, Frontiers in immunology,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.
July 2014, Haemophilia : the official journal of the World Federation of Hemophilia,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
May 2016, Pediatric blood & cancer,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.
December 2015, Thrombosis research,
N C Leksa, and P-L Chiu, and G M Bou-Assaf, and C Quan, and Z Liu, and A B Goodman, and M G Chambers, and S E Tsutakawa, and M Hammel, and R T Peters, and T Walz, and J D Kulman
Pharmacokinetics, Safety, and Efficacy of Recombinant Factor VIII Fc Fusion Protein: A Practical Review.
January 2017, Journal of infusion nursing : the official publication of the Infusion Nurses Society,
Copied contents to your clipboard!